Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 9, Number 7—July 2003

Research

Acute Flaccid Paralysis and West Nile Virus Infection

James J. Sejvar*Comments to Author , A. Arturo Leis†, Dobrivoje S. Stokic†, Jay A. Van Gerpen‡, Anthony A. Marfin*, Risa Webb§, Maryam B. Haddad*, Bruce C. Tierney*, Sally A. Slavinski§, Jo Lynn Polk†, Victor Dostrow†, Michael Winkelmann†, and Lyle R. Petersen*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA; †Methodist Rehabilitation Center, Jackson, Mississippi, USA; ‡Ochsner Clinic, New Orleans, Louisiana, USA; §Mississippi State Department of Health, Jackson, Mississippi, USA

Main Article

Table 1

Serologic results for West Nile virus (WNV)–specific antibodies in patients with acute flaccid paralysis associated with acute WNV infectiona

IgM-capture enzyme immunoassay Plaque reduction neutralization assay
Case
Onset
Collection
Sample
SLEV
WNV
SLEV
WNV
1
6/24
7/12
Serum
3.5
22.3
320
5,120








2
7/12
7/16
Serum
8.0
22.7
80
1,280








3
7/26
8/1
Serum
2.79
24.9
<10
640








4
7/29
8/3
Serum
1.1
14.1
<10
80
4
7/29
8/3
CSF
3.3
39.2


4
7/29
8/13
Serum
4.4
23.5
40
2,560








5
8/11
8/15
Serum

2.02


5
8/11
8/29
Serum
3.4
25.7










6
8/13
8/16
CSF
6.1
23.8


6
8/13
8/16
Serum
1.0
5.7
<10
40








7
9/1
10/24
Serum
2.8
10.6
10
320
7 9/1 9/6 CSF Not performed 7.4

aIgM, immunoglobulin M; SLEV, Saint Louis encephalitis virus; CSF, cerebrospinal fluid.

Main Article

TOP